Intrahepatic Cholangiocarcinoma: A Summative Review of Biomarkers and Targeted Therapies

被引:24
作者
Acher, Alexandra W. [2 ]
Paro, Alessandro [2 ]
Elfadaly, Ahmed [2 ]
Tsilimigras, Diamantis [2 ]
Pawlik, Timothy M. [1 ,2 ]
机构
[1] Ohio State Univ Wexner Med Ctr, James Comprehens Canc Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, James Comprehens Canc Ctr, Wexner Med Ctr, Columbus, OH 43210 USA
关键词
intrahepatic; cholangiocarcinoma; biomarkers; outcomes; trials; METASTATIC CHOLANGIOCARCINOMA; TYROSINE KINASE; RISK-FACTORS; OPEN-LABEL; MUTATIONS; EPIDEMIOLOGY; MULTICENTER; EXPRESSION; FREQUENCY; GENE;
D O I
10.3390/cancers13205169
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although rare, intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy and the incidence of ICC has increased 14% per year in recent decades. Treatment of ICC remains difficult as most people present with advanced disease not amenable to curative-intent surgical resection. Even among patients with operable disease, margin-negative surgical resection can be difficult to achieve and the incidence of recurrence remains high. As such, there has been considerable interest in systemic chemotherapy and targeted therapy for ICC. Over the last decade, the understanding of the molecular and genetic foundations of ICC has reshaped treatment approaches and strategies. Next-generation sequencing has revealed that most ICC tumors have at least one targetable mutation. These advancements have led to multiple clinical trials to examine the safety and efficacy of novel therapeutics that target tumor-specific molecular and genetic aberrations. While these advancements have demonstrated survival benefit in early phase clinical trials, continued investigation in randomized larger-scale trials is needed to further define the potential clinical impact of such therapy.
引用
收藏
页数:15
相关论文
共 65 条
[11]   The Landmark Series: Intrahepatic Cholangiocarcinoma [J].
Cloyd, Jordan M. ;
Ejaz, Aslam ;
Pawlik, Timothy M. .
ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (08) :2859-2865
[12]   Mechanisms of receptor tyrosine kinase activation in cancer [J].
Du, Zhenfang ;
Lovly, Christine M. .
MOLECULAR CANCER, 2018, 17
[13]   Intrahepatic cholangiocardnoma - Rising frequency, improved survival, and determinants of outcome after resection [J].
Endo, Itaru ;
Gonen, Mithat ;
Yopp, Adam C. ;
Dalal, Kimberly M. ;
Zhou, Qin ;
Klimstra, David ;
DAngelica, Michael ;
DeMatteo, Ronald P. ;
Fong, Yuman ;
Schwartz, Lawrence ;
Kemeny, Nancy ;
O'Reilly, Eileen ;
Abou-Alfa, Ghassan K. ;
Shimada, Hiroshi ;
Blumgart, Leslie H. ;
Jarnagin, William R. .
ANNALS OF SURGERY, 2008, 248 (01) :84-96
[14]   PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma [J].
Fontugne, Jacqueline ;
Augustin, Jeremy ;
Pujals, Anais ;
Compagnon, Philippe ;
Rousseau, Benoit ;
Luciani, Alain ;
Tournigand, Christophe ;
Cherqui, Daniel ;
Azoulay, Daniel ;
Pawlotsky, Jean-Michel ;
Calderaro, Julien .
ONCOTARGET, 2017, 8 (15) :24644-24651
[15]  
Furubo S, 1999, HISTOPATHOLOGY, V35, P230
[16]   Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma [J].
Goeppert, Benjamin ;
Roessler, Stephanie ;
Renner, Marcus ;
Singer, Stephan ;
Mehrabi, Arianeb ;
Vogel, Monika Nadja ;
Pathil, Anita ;
Czink, Elena ;
Koehler, Bruno ;
Springfeld, Christoph ;
Pfeiffenberger, Jan ;
Rupp, Christian ;
Weiss, Karl Heinz ;
Schirmacher, Peter ;
Doeberitz, Magnus von Knebel ;
Kloor, Matthias .
BRITISH JOURNAL OF CANCER, 2019, 120 (01) :109-114
[17]   The V599E BRAF mutation is uncommon in biliary tract cancers [J].
Goldenberg, D ;
Rosenbaum, E ;
Argani, P ;
Wistuba, II ;
Sidransky, D ;
Thuluvath, PJ ;
Hidalgo, M ;
Califano, J ;
Maitra, A .
MODERN PATHOLOGY, 2004, 17 (11) :1386-1391
[18]   Targeting FGFR inhibition in cholangiocarcinoma [J].
Goyal, Lipika ;
Kongpetch, Sarinya ;
Crolley, Valerie E. ;
Bridgewater, John .
CANCER TREATMENT REVIEWS, 2021, 95
[19]   Epidemiology and risk factors: intrahepatic cholangiocarcinoma [J].
Gupta, Amar ;
Dixon, Elijah .
HEPATOBILIARY SURGERY AND NUTRITION, 2017, 6 (02) :101-104
[20]   Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas [J].
Gwak, GY ;
Yoon, JH ;
Shin, CM ;
Ahn, YJ ;
Chung, JK ;
Kim, YA ;
Kim, TY ;
Lee, HS .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2005, 131 (10) :649-652